Maxim Group Reiterates Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)

Maxim Group reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $12.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright restated a buy rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics has an average rating of Moderate Buy and a consensus price target of $20.00.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $5.05 on Tuesday. The company’s fifty day moving average is $4.37 and its two-hundred day moving average is $5.18. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $7.28. The firm has a market capitalization of $161.49 million, a price-to-earnings ratio of -5.80 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, sell-side analysts expect that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $426,000. Renaissance Technologies LLC increased its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC boosted its position in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the second quarter valued at about $147,000. Finally, Bank of New York Mellon Corp grew its stake in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.